ArticleJournal of translational medicine2025
Fibro-NPC: a pathogenic subtype identified at single-cell resolution with secreted SFRP4 as a biomarker in intervertebral disc degeneration.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Versatile Microgel Platform for Intervertebral Disc Degeneration Therapy: Targeting Pericyte-Mediated Fibrosis and Protecting Nucleus Pulposus Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Genetic interaction betweenbioRxiv : the preprint server for biology · 2026Article
- Genetic interaction betweenResearch square · 2026Article
- Integrative bulk and single-cell transcriptomic analyses reveal nucleus pulposus cell fibrosis as a therapeutic target in intervertebral disc degeneration and identify quercetin as a potential antifibrotic agent.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Integrative Transcriptomics Across Etiologies Reveals Common and Disease-Specific Fibrogenic Signatures in Liver Fibrosis.Canadian journal of gastroenterology & hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntervertebral disc degeneration (IDD) is a primary cause of low back pain and, in severe cases, can lead to disability. Current treatments for low back pain remain limited in efficacy, underscoring the need for a deeper understanding of the molecular mechanisms driving IDD. The degeneration process is primarily driven by an imbalance in the extracellular matrix, largely due to the senescence of nucleus pulposus cells (NPCs).
methodsThrough single-cell sequencing of degenerated nucleus pulposus tissue from five intervertebral discs, we identified five distinct NPC subtypes. Notably, fibrosis-associated NPCs (Fibro-NPC) were predominantly observed at the terminal stage of cell differentiation, identifying Fibro-NPC as a pathogenic subtype in IDD. To further explore intercellular interactions, we used the CellChat algorithm to construct a cell communication network encompassing the diverse cell types in the nucleus pulposus. Mass spectrometry analysis of normal and degenerated tissue subsequently identified seven core proteins associated with IDD. Among these, WGCNA and machine learning highlighted SFRP4 as a central pathogenic protein, highly expressed in Fibro-NPC.
resultsAdvanced differentiation of nucleus pulposus cells, particularly the Fibro-NPC subtype, is associated with the secretion of SFRP4, which accelerates cellular senescence. This senescence contributes to fibrosis within the nucleus pulposus, along with angiogenesis and inflammatory infiltration in the nucleus pulposus microenvironment. Collectively, these processes drive intervertebral disc degeneration.
conclusionsOur findings position SFRP4 as a biomarker for IDD, presenting a novel target for its diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.